4
Heath and coworkers analyzed the effect of AS mutations on FGFR2c binding to FGF1, FGF2 and FGF4, using surface plasmon resonance (SPR), and found that both AS mutations enhance the binding affinity of FGFR2c for FGF2 only, with the S252W mutation causing a greater increase (19) . Hence, it was proposed that craniofacial pathology is mediated by enhanced signaling of FGF2 through mutant FGFR2c and that the more severe craniofacial pathology in S252W AS patients reflects the greater enhancement in FGF2 binding.
Analogously, it was postulated that the greater severity of syndactyly in P253R AS patients, relative to S252W AS patients, reflects the higher affinity of P253R FGFR2b for FGF7 or FGF10 (19) .
Wilkie and coworkers identified two AS and two PS patients harboring Alu-element insertions or nucleotide substitutions, which affected alternative splicing of FGFR2 and resulted in the ectopic expression of FGFR2b in the patients' mesenchymal tissues (20) . Notably, the severity of the limb phenotype correlated with the level of ectopic FGFR2b expression, as the AS patient had higher levels of ectopic FGFR2b expression compared to the levels of ectopic FGFR2b expression in PS patients. Hence, Wilkie and coworkers proposed that autocrine activation of ectopic mesenchymal FGFR2b by mesenchymally expressed FGF7 or FGF10 leads to syndactyly. In contrast to the data of Anderson et al. (1998) , Ornitz and coworkers did not observe increased binding of AS mutant FGFR2c to FGF2 (21) . Instead, they showed that AS mutations violate FGFR2 ligand binding specificity (21) . Cell lines expressing S252W FGFR2c were stimulated by FGF7 and FGF10, ligands that have absolutely no activity on cell lines expressing wild-type FGFR2c. Conversely, cell lines expressing S252W FGFR2b were also shown to respond to FGF2, which normally has no activity on cell lines expressing wild type FGFR2b. Moreover, binding of FGF7 to both AS mutant FGFR2c was also demonstrated. Recently, a kindred remarkable for Apert-like syndactyly in the absence of craniosynostosis was found to segregate two mutations, S252L and A315S, in cis (23). These mutations respectively map to the D2-D3 linker region ( Fig. 1 ) and the alternatively spliced βC′-βE loop (Fig. 1) , a region that dictates the ligand binding specificity of FGFR2. Notably, the A315S substitution changes a FGFR2c specific residue to a FGFR2b specific residue, and led Wilkie and coworkers to hypothesize that the double mutation results in syndactyly by enabling S252L/A315S FGFR2c to bind FGF7 or FGF10. Apert-like syndactyly has also been reported in a PS patient with a D321A mutation (24), which also maps to the alternatively spliced βC′-βE loop of FGFR2c ( Fig. 1 ) and further implicates mutant FGFR2c signaling in the pathogenesis of 6 craniosynostosis and syndactyly. Because S252L, A315S and D321A mutations map to key regions in the ligand binding site of FGFR2c (25) they are likely to be ligand-dependent mutations. Here, we examine the effect of the two canonical AS mutations, the D321A PS mutation and the S252L/A315S double mutation on FGFR2 ligand binding affinity and specificity in order to further understand how cranial and limb phenotypes dissociate in patients with different pathogenic FGFR2 mutations. Fig. 2A) , the FGF3/5 subfamily (6.3-8.2 fold) (Fig. 2C) , the FGF4/6 subfamily (4.9-6 fold) (Fig. 2B ) and FGF23 (4.2 fold) (Fig. 2H) . The enhancement in binding affinity of S252W FGFR2c for the FGF8/17/18 subfamily is less remarkable (1.6-2.8 fold) (Fig. 2F) .
Importantly, injection of S252W FGFR2c on to FGF10 sensor chips results in a significant increase in RU, compared to wild type FGFR2c, as shown in Fig. 2D . Kinetic analysis of the S252W FGFR2c-FGF10 interaction yields a K D value of 1440 nM. Hence, the S252W mutation violates FGFR2c ligand binding specificity and agrees with the findings of Yu et al. (2000) . The S252W mutation has an even more profound effect on FGFR2c binding to FGF19, and enables high affinity binding (K D = 103 nM) (Fig. 2G) . In contrast to the findings of
Yu et al. (2000)
, we were unable to detect any significant effect of the S252W mutation on the FGFR2c-FGF7 interaction. Binding of FGF21 to S252W FGFR2c is not observed.
The binding affinities of P253R FGFR2c for FGF9/16/20 subfamily members (7.4-34 fold) ( Fig. 2E and Table 1) were most robustly enhanced, followed by FGF8/17/18 subfamily members (3.5-10.6 fold) ( Fig. 2F and Table 1 ). For the remaining ligands, the P253R mutation enhances ligand binding affinity to a lesser degree than the S252W mutation does (Table 1) .
Binding of P253R FGFR2c was increased for the FGF1/2 subfamily (2.3 fold) ( Fig. 2A) , the FGF3/5 subfamily (2.2-3.7 fold) (Fig. 2C) , the FGF4/6 subfamily (3-4.8 fold) (Fig. 2B ) and FGF23 (3.3 fold) (Fig. 2H) to similar extents. Importantly, like the S252W mutation, the P253R mutation also violates FGFR2c ligand binding specificity and enables FGFR2c to bind FGF10 ( Effect of D321A and S252L/A315S mutations on FGFR2c ligand binding affinity and specificity Next, we examined the effect of the D321A mutation and the S252L/A315S double mutation, which manifest only in the FGFR2c splice isoform, on FGFR2c ligand binding affinity and specificity. Importantly, the S252L/A315S double mutation causes syndactyly in the absence of craniosynostosis and therefore provides an attractive opportunity to understand the mechanisms by which craniofacial and limb pathology arise in patients with pathogenic FGFR2 mutations.
The binding of D321A FGFR2c to all FGFs, with the exception of FGF22, was examined.
Unlike the AS mutations, which ubiquitously increase FGFR2c binding to nearly all FGFs, the D321A mutation increases the binding affinity of FGFR2c to a subset of FGFs including FGF3 (2.3 fold), FGF5 (2.7 fold) (Fig. 2C) (Fig. 2E,F) , FGF20 (4.1 fold), and FGF23 (3 fold) (Fig. 2H) (Table 1) . Importantly, like the AS mutations, the D321A mutation also enables FGFR2c to bind FGF10 and FGF19 (Fig. 2D,G) with K D values of 2830 and 255 nM, respectively. The D321A mutation had no major impact on the binding affinities of FGFR2c for FGF1, FGF4 (Fig. 2B) , and FGF9 (Table 1) . Notably, an exceptional loss in FGF2 binding (60 fold) ( Fig. 2A) and mild decreases in FGF6 (1.5 fold) and FGF8 (2 fold) binding are observed for D321A FGFR2c (Table 1) . Interestingly, the effect of the D321A mutation varies even for members within the same FGF subfamily.
The S252L/A315S double mutation also has a variable effect on FGFR2c binding to FGFs ( Fig. 2A-H (Table 2) .
As in the case of FGFR2c, SPR analysis demonstrates that both AS mutations increase the binding affinity of FGFR2b for FGFs (Fig. 3C-F and Table 2 ), and the effect is consistently greater for the S252W mutation. Large increases in the binding affinities of S252W FGFR2b for FGF1 (3.7 fold) (Fig. 3D) , FGF6 (4.5 fold) and FGF7 (8.7 fold) are observed. Increases in binding affinity of S252W FGFR2b for FGF3 (1.9 fold), FGF4 (2.1 fold) and FGF10 (2.1 fold) (Fig. 3C ) are modest. In the case of P253R FGFR2b, a large increase in binding affinity is only observed for FGF7 (4.9 fold) and increases in binding affinity for FGF1 (1.7 fold) (Fig. 3D) , FGF3 (1.19 fold), FGF4 (1.9 fold), FGF6 (3 fold) and FGF10 (1.6 fold) (Fig. 3C) 
Crystallographic analysis of AS mutant FGFR2b
To ascertain if AS mutations enhance FGFR2b binding to FGFs through additional receptorligand contacts, we crystallized S252W FGFR2b-FGF10 and P253R FGFR2b-FGF1 complexes.
Data collection and refinement statistics are given in Table 3 . As we previously reported for AS 
Discussion
The importance of FGF signaling in human skeletal development is highlighted by the numerous mutations in FGFR1-3 that result in craniosynostosis (1-3) and chondrodysplasia syndromes (45) . Elucidation of the molecular basis for AS and other ligand-dependent craniosynostosis syndromes is an important avenue to assess the physiological and pathological roles of various FGFs in craniofacial and limb development. In this study, we examined the effect of AS mutations, the D321A PS mutation and the S252L/A315S double mutation on FGFR2 ligand binding affinity and specificity using SPR. These data show that each of the pathogenic FGFR2 mutations elicit distinct changes in FGFR2 ligand binding affinity and specificity, which correlate to the craniofacial and limb phenotypes observed in patients harboring these mutations. to wild-type mice embryos, at 16.5 and 18.5 days postcoitum (47, 48) . However, this phenotype is suggested to be secondary to a generalized decrease in calvarial bone size, rather than a disruption in cranial suture maturation (47) .
Widespread enhancement of FGF binding correlates with craniosynostosis

Structural basis for the generalized increase in FGF binding affinity by AS mutations
Notably, the general increase in P253R FGFR2c ligand binding affinity is entirely consistent with the structural mode of gain-of-function observed in the P253R FGFR2c-FGF2 structure (22). We have previously shown that the P253R mutation results in three additional hydrogen bonds between receptor and the β8-β9 turn in the core homology region of FGF2 (22). Two of these hydrogen bonds involve backbone carbonyl atoms of FGF2, and therefore should occur in every P253R FGFR2c-FGF interaction. The third hydrogen bond is mediated by the side chain of Asn111 in FGF2. Interestingly, this Asn is conserved in the FGF8/17/18 subfamily and may account for the larger increase in affinity of the mutant receptor for this subfamily.
The ability of the S252W mutation to ubiquitously increase FGFR2c ligand binding affinity is not completely predicted by the S252W FGFR2c-FGF2 structure (22). The S252W mutation was shown to result in an additional hydrogen bond and hydrophobic contact between Furthermore, in the S252W FGFR2c-FGF2 structure, Trp252 inserts into a hydrophobic pocket on D3 between Ile257 and Tyr281. This interaction likely keeps the receptor in a conformation that is more favorable for ligand binding and may also contribute to the generalized increase in FGF binding for S252W FGFR2c.
Binding of FGFR2c to FGF10 correlates with syndactyly
All four pathogenic mutations in this study violate (Tables 1 and 2 ). Nevertheless, these gain of interactions are probably pathological because FGF10 and FGFR2c are both mesenchymally expressed, and the high local concentrations of FGF10 would allow pathological autocrine signaling to take place. Therefore, we suggest that the illegitimate binding and signaling of show that AS mutations violate FGFR2 specificity. However, we did not observe binding of FGF7 to either AS mutant FGFR2c, although this is not surprising given the fact that FGF7 binds to FGFR2b nearly 20 times weaker than FGF10 (Table 2) . Based on our SPR data, we believe that the majority of limb pathology is due to autocrine signaling of mutant FGFR2c through FGF10. This is consistent with genetic studies showing that FGF10 is critical for limb development and outgrowth (57, 58), whereas FGF7 is dispensible for proper limb development (59, 60).
Molecular mechanisms by which pathogenic FGFR2c mutations affect ligand binding specificity
The variable effect of the D321A mutation and the S252L/A315S double mutation on ligand binding is consistent with the crystal structures of highly specific FGFR2c-FGF2 and FGFR2b-FGF10 complexes, which reveal that interactions between FGF ligand and the alternatively spliced βC′-βE loop are major determinants of binding specificity (25, 44). These structures also provide convincing explanations by which pathogenic mutations in the βC′-βE loop reduce FGFR2c binding to FGF2 and concomitantly enhance FGFR2c binding to FGF10 (Fig. 2A, D) .
The dramatic loss of FGF2 binding to D321A FGFR2c can readily be explained by the crystal structure of the wild type FGFR2c-FGF2 complex. In this structure, Asp321 makes three hydrogen bonds with FGF2 (25) and the huge loss in FGF2 binding by D321A FGFR2c reflects the elimination of these interactions. The loss of FGF2 binding to S252L/A315S FGFR2c can also be accounted for by the crystal structure of the wild type FGFR2c-FGF2 complex. In this structure, Ala315 makes intramolecular interactions that facilitate a βC′-βE loop conformation optimal for FGF2 binding, thus indirectly contributing to ligand binding affinity. It is noteworthy that the A315S mutation causes a greater loss in FGF2 binding, compared to the S252L/A315S double mutation, and suggests that the S252L mutation partially rescues the loss of FGF2 binding (data not shown).
The available structural data also provide molecular explanations for the ability of the D321A mutation and the S252L/A315S double mutation to confer FGF10 binding. In a hypothetical FGFR2c-FGF10 model, the side chain of Asp321 is in major steric clash as well as in charge repulsion with Asp78 in the N-terminus of FGF10, and explains why wild type FGFR2c rejects FGF10. Removal of both the steric and electrostatic conflicts by the D321A mutation likely accounts for the large gain in FGF10 binding by D321A FGFR2c. The molecular basis for the ability of the S252L/A315S double mutation to confer FGF10 binding upon FGFR2c can be inferred from available structural data. In the wild type FGFR2b-FGF10 structure (44), Ser315, a residue that is highly conserved in FGFR2b, makes two hydrogen bonds with Asp78, a residue unique to the FGF7/10/22 subfamily. Hence, the A315S substitution should enable FGFR2c to make hydrogen bonds with Asp78 of FGF10 and contribute to a gain in FGF10 binding. The S252L mutation likely enhances the interaction of FGFR2c with FGF10 by introducing a similar, but weaker, hydrophobic contact as described for the S252W mutation (see below). It is likely that these two mutations synergize to enable FGFR2c to bind FGF10. The mechanism by which the S252W mutation enables FGFR2c to bind FGF10 can be gleaned from the crystal structure of the S252W FGFR2b-FGF10 complex reported in this article. Based on this structure, we predict that Leu73 in αN of FGF10 will engage in analogous hydrophobic contact with S252W FGFR2c. Finally, the gain in binding of P253R FGFR2c to FGF10 is fully expected based on the highly conserved nature of the gain-of-function hydrogen bonds mediated by the P253R mutation.
A potential role for FGFR2b in AS
The SPR data show that AS mutations enhance and violate FGFR2b ligand binding affinity and specificity, respectively, although the relative increases in FGF binding are generally less remarkable than for FGFR2c. Heath and coworkers suggest that syndactyly in AS is mediated by elevated FGFR2b signaling by FGF7 or FGF10 (19) . However, the greater enhancement of S252W FGFR2b binding to FGF7 and FGF10, relative to P253R FGFR2b, is not consistent with the relative severity of syndactyly between the two AS mutations (13) (14) (15) . Additionally, missense mutations that selectively manifest in FGFR2c can cause syndactyly, and therefore, it is unclear if elevated FGFR2b signaling plays a major role in mediating syndactyly. FGFR2b is expressed on epithelial cells of ectodermal and endodermal origin and is critical for skin development (61-63). It is possible that enhanced signaling by AS mutant FGFR2b accounts for unique dermatological phenotypes in AS, such as hyperhidrosis, hypopigmentation and severe widespread acne (5). Indeed, an otherwise normal patient who presented for severe localized acne was found to have the AS Ser252Trp mutation in FGFR2b from lesional epidermal cells, whereas unaffected areas were found to contain wild-type FGFR2b (64).
Concluding remarks
In summary, analyses of pathogenic ligand-dependent FGFR2 mutations by several laboratories have established that these mutations violate the rules governing FGFR ligand binding affinity and specificity. Based on these data, we suggest that craniosynostosis is mediated by the enhancement of FGFR2c signaling by a number of FGFs, whereas syndactyly is caused by illegitimate signaling of mutant FGFR2c through FGF10. Genetic studies are needed to substantiate these binding data and will likely require the development of more advanced genetic tools. Additional biochemical and crystallographic characterization of these mutant receptors should provide further insight into the mechanism by which ligand binding specificity is bypassed and will facilitate the design of antagonists capable of alleviating the deleterious effect of these mutations. 
Materials and methods
Protein expression and purification
Recombinant full length human FGFs, FGF1 through FGF10 and FGF16 through FGF23, with the exception of FGF22, were expressed in Escherichia coli. FGF homologous factor 1b (FHF1b) (formally known as FGF12b) was also produced in E.coli. Soluble FGFs (FGF1, FGF2, and FGF10) and FHF1b were purified by heparin affinity, ion exchange and size exclusion chromatography as previously described (35). FGF7 was generously provided by Amgen (Amgen Inc.). Insoluble FGFs (FGF3, FGF5, FGF6, FGF8, FGF16 through FGF21) were refolded in vitro and subsequently purified in a similar manner to soluble FGFs. FGF4 and FGF9
were purified through salt extraction and ammonium sulfate precipitation, respectively, and then purified as soluble FGFs. The expression and purification of FGF23 is described elsewhere (65).
The "b" isoforms of FGF8 and FGF17 were used in this study. S252W, P253R, D321A, and S252L/A315S point mutations were introduced into the FGF-binding portion of human FGFR2c (residues 147-366) and S252W and P253R point mutations were introduced into the FGF-binding portion of human FGFR2b (residues 140-369) by using the Quik Change site-directed mutagenesis kit (Stratagene). Wild type and mutant FGFRs were expressed in E.coli and refolded in vitro using a previously described protocol (25).
Briefly, cells were induced with IPTG for 5 hr, centrifuged, and the bacterial pellet was lysed in 25 mM K-Na phosphate buffer (pH 7.5) containing 150 mM NaCl, 2 mM EDTA, and 10% glycerol using a French press. Following centrifugation, the pellets were dissolved in 6 M guanidinium hydrochloride and 10 mM DTT in 100 mM Tris-HCl buffer (pH 8.0). The solubilized wild type and mutant FGFRs were refolded by dialysis against 25 mM HEPES buffer (pH 7.5) containing 150 mM NaCl, 10% Glycerol, and 1 mM L-Cysteine. Wild-type and mutant FGFRs were subsequently purified using heparin affinity and size exclusion chromatography.
Surface plasmon resonance analysis of FGFR-FGF interactions
Kinetic data for wild type and mutant FGFR2-FGF interactions were characterized using a BIAcore 3000 instrument (Biacore AB, Uppsala, Sweden) as previously described (35 
SPR data analysis
Reference responses from the control flow cell, containing FHF1b, were subtracted from FGF flow cells for each analyte injection using BiaEvaluation software (Biacore AB, Uppsala, 
Crystallization and data collection
The S252W FGFR2b-FGF10 complex was crystallized under similar conditions as described for the wild type glycerol as cryo-protectant. A 2.1 Å data set for the P253R FGFR2b-FGF1 complex was collected on a CCD detector at beamline X4A at the National Synchrotron Light Source, Brookhaven National Laboratory. Data were processed using DENZO and SCALEPACK (66) .
Structure determination and refinement
Rigid body refinement was used to place one copy of the wild type FGFR2b-FGF10 complex (PDB ID: 1NUN) (44) into the unit cell of S252W FGFR2b-FGF10 crystal. The crystal structure of the P253R FGFR2b-FGF1 complex was solved using molecular replacement (67) Kinetic data are summarized in Table 2 . 
